Glucagon-Like Peptide-1. The hormone targeted by semaglutide and tirzepatide. Three Cochrane reviews confirmed efficacy (2025). FDA approved the pill (Dec 2025). Stanford identified genetic variants affecting ~10% of response rates (2026).
Appears across 2 pieces (1 defined it · 1 discussed it in essays): when this term was part of the conversation. First surfaces May 2026.
